Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Inhibits JAK1 and TYK2, reducing signalling downstream of cytokine receptors that use these kinases. This is a pharmacological description of the investigational molecule; it should not be represented as a currently authorised therapy or a product-specific clinical mechanism unless a marketing authorisation is confirmed.
Indications / reported uses
Investigated for dermatomyositis and other immune-mediated inflammatory diseases. The catalogue entry is not assigned an authorised therapeutic indication without a current product label or marketing authorisation.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Brepocitinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Brepocitinib Permitted Daily Exposure (PDE) report (the Brepocitinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Brepocitinib Occupational Exposure Limit (OEL) report (the Brepocitinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.